Disc Medicine's DISC-0974 Shows Strong Anemia Responses in Myelofibrosis Phase 2 Trial
Event summary
- Disc Medicine presented updated Phase 2 trial data for DISC-0974 at ASCO 2026, showing durable anemia responses in myelofibrosis patients regardless of baseline transfusion status.
- 55% of non-transfusion-dependent patients achieved a major hemoglobin response, while 64% of low-transfusion-burden patients achieved transfusion independence.
- DISC-0974 demonstrated efficacy both with and without concomitant JAK inhibitor therapy, with 56% of patients on JAK inhibitors achieving a major hematologic response.
- The trial enrolled 61 patients as of April 27, 2026, with an end-of-Phase 2 meeting with the FDA expected by year-end.
The big picture
Disc Medicine's positive Phase 2 data for DISC-0974 underscores the unmet need in treating myelofibrosis-associated anemia, a condition with few effective therapies. The trial's success across diverse patient subgroups, including those on JAK inhibitors, positions DISC-0974 as a potential first-in-class treatment. The upcoming FDA meeting will be critical in determining the next steps for this promising hematologic therapy.
What we're watching
- Regulatory Pathway
- Whether the FDA's end-of-Phase 2 meeting will accelerate DISC-0974's development timeline.
- Market Potential
- The pace at which Disc Medicine can expand DISC-0974's patient population beyond myelofibrosis.
- Competitive Positioning
- How Disc Medicine differentiates DISC-0974 in a space with limited treatment options for MF-associated anemia.
Related topics